National Gynecologic Oncology Fellows Forum April 2-5, 2025 Fountainbleu Hotel and Resort Miami, Florida

WEDNESDAY, APRIL 2, 2025	5	
Time	Description	
4:00 pm - 6:00 pm	Registration & Badge Pick-up	
6:00 PM - 7:30 PM	Welcome Reception	
THURSDAY, APRIL 3, 2025		
Time	Description	Speaker
7:00 AM - 8:00 AM	Breakfast & Registration	
	General Session 1	
8:00:00 AM - 9:45 am	Moderators:	
8:00 am - 8:10 am	Welcome & Opening Remarks	
	Adapting to a New Era: The SHAPE Trial and Its potential Effect on Surgical Management and	Chelsea Stewart, MD, University of Tennessee Health Science
8:10 am - 8:20 am	Fellow Education in Cervical Cancer	Center
·		Sharonne Holtzman, MD, Icahn School of Medicine at The Mount
8:20 am - 8:30 am	Mapping Shared Neoantigens and T cell Dysregulation in MSI-H Endometrial Cancer Patients	Sinai Hospital
	Higher socioeconomic status does not improve endometrial cancer survival for Black women in	
8:30 am - 8:40 am	the United States	Larissa Weirich, MD, Emory University
	Spatial genomic analysis of MLH1 hypermethylated and Lynch syndrome endometrial cancers	Sagar Chokshi, MD, University of South Alabama Mitchell Cancer
8:40 am - 8:50 am	reveals key differences in the tumor immune microenvironment	Institute
8:50 am - 9:00 am	Discussion/Audience Q&A	
	Association of Artificial Intelligence-based Analysis of Body Composition and Surgical Outcomes	
9:00 am - 9:10 am	in Gynecologic Cancers	Luxue Deng, MD, Roswell Park Comprehensive Cancer Center
	How Are We Caring for the Oldest Ovarian Cancer Patients? Evaluating Post EWOC-1	
9:10 am - 9:20 am		Jude Nawlo, MD, New York University
	, , , , , , , , , , , , , , , , , , , ,	Connor Wang, MD, Northwestern University Feinberg School of
9:20 am - 9:30 am		Medicine
	Sentinel lymph node mapping in women with endometrial cancer with a preoperative diagnosis	
9:30 am - 9:40 am		Divya Gowthaman, MD, Northwell Gynecologic Oncology
9:40 am - 9:55 am	Discussion/Audience Q&A	
9:55 am - 10:25 am	Coffee Break	
10:25 am - 10:55 am	Faculty Lecture: Trial Design/Basic Stats	Mario Leitao, MD, Memorial Sloan Kettering Cancer Center

THURSDAY, APRIL 3, 2025, Continued				
Time	Description	Speaker		
10:55 am - 12:30 pm	General Session 2			
	Concordance and frequency of TP53 protein expression and gene sequence in mismatch repair			
	proficient (pMMR) and POLE wild-type endometrial cancer: An Endometrial Cancer Molecularly			
10:55 am - 11:05 am	Targeted Therapy Consortium database study	Nujsaubnusi Vue, MD, Allegheny Health Network		
	Postoperative complications in gynecologic oncology patients receiving therapeutic			
11:05 am - 11:15 am	anticoagulation	Hannah McLaughlin, MD, University of Michigan		
	Improvements and Disparities in Survival for High-Grade Serous Ovarian Cancer: A			
11:15 am - 11:25 am	Contemporary Assessment of Real-World Patients	Ahmed Hussain, MD, Walter Reed National Military Medical Center		
11:25 am - 11:35 am	Rare Ovarian Adenocarcinomas Exhibit a Distinct Germline Landscape	Corbyn Nchako, MD, Memorial Sloan Kettering Cancer Center		
11:35 am - 11:50 am	Discussion			
	Onvansertib in combination with carboplatin demonstrates enhanced anti-tumorigenic effects			
11:50 am - 12:00pm	in pre-clinical models of serous endometrial cancer	Glenn Boyles, MD, University of North Carolina		
	Adjuvant Chemotherapy Does Not Appear to Improve Survival in Patients with 2009 FIGO Stage			
12:00 pm - 12:10 pm	I Uterine Serous Carcinoma without Myoinvasion	Stephen Graves, MD, Memorial Sloan Kettering Cancer Center		
12:10 pm - 12:20 pm	Pembrolizumab plus lenvatinib in women with advanced or recurrent uterine carcinosarcoma	Qi Zhang, MD, Atrium Levine Cancer Institute		
12:20 pm - 12:30 pm	Discussion			
12:30 pm - 2:00pm	Group Luncheon: Invited Guest Speaker, Dr. Ronald Alvarez			
2:30 pm - 5:30 pm	Team Building Event on the Beach			
6:00 pm - 9:00 pm	Margaritaville Dinner			

FRIDAY, APRIL 4, 2025		
Time	Description	Speaker
7:00 AM - 8:00 AM	Breakfast & Registration Help Desk	5,5000
8:00 am - 10:00 am	General Session 3	
8:00 am - 8:10 am	Welcome & Opening Remarks	
	Examining Activin A Expression as a Biomarker in Platinum-Sensitive and Platinum-Refractory	
8:10 am - 8:20 am	High-Grade Serous Ovarian Cancer	Emily O'Brien, MD, University of Alabama at Birmingham
	Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug	
8:20 am - 8:30 am	conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine serous carcinoma	Michelle Greenman, MD, Yale University School of Medicine
8:30 am - 8:40 am	Predictors of treatment delay and prolongation in locally advanced cervical cancer	Maya Gross, MD, University of Washington
8:40 am - 8:50 am	The Impact of Microbial Driven Inflammation on Cervical Cancer Cells	Ann Mercier, MD, Icahn School of Medicine at Mt Sinai Hospital
8:50 am - 9:05 am	Discussion	
9:05 am - 9:15 am	Utility of Preoperative Imaging in Endometrial Carcinoma	Clarissa Lam, MD, Memorial Sloan Kettering Cancer Center
	Ultrasonography based measurements of endometrial thickness in patients with p53 abnormal	
9:15 am - 9:25 am	endometrial carcinomas	Rachel Mojdehbakhsh, MD, University of Wisconsin
9:25 am - 9:35 am	Clinically node-positive cervical cancer: does surgery have a role?	Jenna Zimmerman, MD, Allegheny Health Network
	The effectiveness of low-pressure pneumoperitoneum on post-operative outcomes in	
9:35 am - 9:45 am	gynecologic oncology surgery	Vasanti Jhaveri, MD, St. Luke's University Health Network
9:45 am - 10:00 am	Discussion	
		Christine Walsh, MD, University of Colorado - Anschutz Medical
10:00 am - 10:30 am	Faculty Lecture: Time Management	Campus
10:30 am - 11:00 am	Coffee Break	
11:00 am - 12:40 pm	General Session 4	
11:00 am - 12:40 pm	General Session 4 Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of	
11:00 am - 12:40 pm 11:00 am - 11:10 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis)	Katherine Baumann, MD, Beth Israel Deaconess Medical Center
·	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical	Katherine Baumann, MD, Beth Israel Deaconess Medical Center Julia Salinaro, MD, Program in Women's Oncology, Women and
·	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers	· ·
11:00 am - 11:10 am 11:10 am - 11:20 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University
11:00 am - 11:10 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes	Julia Salinaro, MD, Program in Women's Oncology, Women and
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am 11:55 am - 12:05 pm 12:05 pm - 12:15 pm	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center Jill Roberts, MD, University of Miami Hospital/Sylvester Cancer
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am 11:55 am - 12:05 pm 12:05 pm - 12:15 pm	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a Higher Progression-Free Survival	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am 11:55 am - 12:05 pm 12:05 pm - 12:15 pm 12:15 pm - 12:25 pm 12:25 pm - 12:40 pm	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a Higher Progression-Free Survival Discussion & Day 2 Remarks	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center Jill Roberts, MD, University of Miami Hospital/Sylvester Cancer
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am 11:55 am - 12:05 pm 12:05 pm - 12:15 pm 12:15 pm - 12:25 pm 12:25 pm - 12:40 pm 12:40 pm - 1:40 pm	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a Higher Progression-Free Survival Discussion & Day 2 Remarks Group Luncheon	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center Jill Roberts, MD, University of Miami Hospital/Sylvester Cancer
11:00 am - 11:10 am 11:10 am - 11:20 am 11:20 am - 11:30 am 11:30 am - 11:40 am 11:40 am - 11:55 am 11:55 am - 12:05 pm 12:05 pm - 12:15 pm 12:15 pm - 12:25 pm 12:25 pm - 12:40 pm	Longitudinal analysis of pharmacy costs among ovarian cancer patients since introduction of poly (ADP-ribose) polymerase inhibitors (PARPis) Creation of a low cost, efficient system to map tumor molecular profiling data into a clinical genomics database for gynecologic cancers Remote perioperative telemonitoring in gynecologic cancer patients is associated with improved patient centered outcomes Impact of State Biomarker Testing Mandates on Access to Precision Medicine and Health Equity in Gynecologic Cancer Care Discussion The impact of Janus kinase 1 (JAK1) mutations and major histocompatibility complex class I (MHC-I) expression on response to immune checkpoint inhibition in endometrial cancer Clinicopathologic features and survival outcomes in women with uterine versus retroperitoneal leiomyosarcoma Use of Mirvetuximab Soravtansine-Gynx in Combination with Bevacizumab is Associated with a Higher Progression-Free Survival Discussion & Day 2 Remarks	Julia Salinaro, MD, Program in Women's Oncology, Women and Infant's Hospital, Brown University Vinita Popat, MD, City of Hope Rita Sartor, MD, Penn Medicine Erica Carballo, MD, Vanderbilt University Medical Center Christina Curtin, MD, Memorial Sloan Kettering Cancer Center Jill Roberts, MD, University of Miami Hospital/Sylvester Cancer

SATURDAY, APRIL 5, 2025		
Time	Description	Speaker
8:00 am - 9:00 am	Breakfast & Registration/Help Desk	
9:00 am - 10:45 am	General Session 5	
9:00 am - 9:10 am	Welcome & Opening Remarks	
	The decline of radical hysterectomies performed by gynecologic oncologists in the United	
9:10 am - 9:20 am	States: 2004-2020	Alicia Youssef, MD, MGH
	Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer	
9:20 am - 9:30 am	patients in the era of same day minimally invasive hysterectomy	Sarah Bell, MD, UPMC
	Correlation between the administration of SARS-CoV-2 vaccinations and infusion-related	Bethany Werner, MD, The University of Oklahoma Health Sciences
9:30 am - 9:40 am	hypersensitivity reactions with taxane administration in patients with gynecologic malignancies	Center
	Disparities in immunotherapy use for primary treatment of advanced cervical cancer prior to	
9:40 am - 9:50 am	Federal Drug and Administration approval: a National Cancer Database study (2014-2021)	Patrick Penalosa, MD, UC San Diego Health, Moores Cancer Center
9:50 am - 10:05 am	Discussion	
	De-escalation of Radiation Therapy in Advanced Endometrial Cancer: Analysis of the National	
10:05 am - 10:15 am	Cancer Database	Judy Hayek, MD, Maimonides/SUNY Downstate HSU
	Resistance mechanisms of FOLR1 antibody–drug conjugate therapy in recurrent high-grade	
10:15 am - 10:25 am	serous ovarian cancer	Matthew Flint, MD, Memorial Sloan Kettering Cancer Center
	The utility of circulating tumor DNA for detecting recurrence during surveillance in patients	
10:25 am - 10:35 am	with high-risk uterine cancer	Allison Walker, MD, St. Luke's University Health Network
10:35 am - 10:45 am	Discussion	
10:45 am - 11:00 am	Coffee Break	
11:00 am - 11:30 am	Faculty Lecture: Publishing	Susan Modesitt, MD, Winship Cancer Institute of Emory University
11:30 am - 12:40 pm	General Session 6	
	NSC59984 is a potent radiosensitizer and cytotoxic agent in in vitro and in vivo models of	
11:30 am - 11:40 am	TP53mut endometrial cancer	Camilla Yu, MD, Cleveland Clinic Foundation
	Identification of Quorum Sensing Meolecules in Endometrial Cancer: Exploring Vaginal	Ana Rosario Santos, MD, University of Miami/Jackson Health
11:40 am - 11:50 am	Microbiome Interactions as a Risk Biomarker	System
	A Lower Rate of Homologous Recombination Deficiency in Epithelial Ovarian Cancer Patients in	Anya Laibangyang, MD, University of Tennessee Health Science
11:50 am - 12:00 pm	the Mid-South	Center
	Homologous recombination (HR) status influences response to hyperthermic intraperitoneal	
12:00 pm - 12:10 pm	chemotherapy (HIPEC) at the time of interval debulking surgery (IDS) for ovarian cancer	Khrystyna Levytska, MD, Cedars-Sinai Medical Center
	Cross-Language Insights: Comparing Spanish and English-Language Cervical Cancer Content on	Jessica Velasquez, MD, The Ohio State University Wexner Medical
12:10 pm - 12:20 pm	TikTok	Center
12:20 pm - 12:40 pm	Discussion	
12:40 pm - 1:00 pm	ТВА	
1:00 pm - 2:30 pm	Awards Celebration Luncheon	Awards and Celebration, Closing Remarks